CONTEXT: Thyroid cancer is the most common form of endocrine cancer, and it is a disease whose incidence is rapidly rising. Well-differentiated epithelial thyroid cancer can be divided into papillary thyroid cancer (PTC) and follicular thyroid cancer (FTC). Although FTC is less common, patients with this condition have more frequent metastasis and a poorer prognosis than those with PTC. OBJECTIVE: The objective of this study was to characterize the molecular mechanisms contributing to the development and metastasis of FTC. DESIGN: We developed and characterized mice carrying thyroid-specific double knockout of the Prkar1a and Pten tumor suppressor genes and compared signaling alterations observed in the mouse FTC to the corresponding human tumors. SETTING: The study was conducted at an academic research laboratory. Human samples were obtained from academic hospitals. PATIENTS: Deidentified, formalin-fixed, paraffin-embedded (FFPE) samples were analyzed from 10 control thyroids, 30 PTC cases, five follicular variant PTC cases, and 10 FTC cases. INTERVENTIONS: There were no interventions. MAIN OUTCOME MEASURES: Mouse and patient samples were analyzed for expression of activated cAMP response element binding protein, AKT, ERK, and mammalian target of rapamycin (mTOR). Murine FTCs were analyzed for differential gene expression to identify genes associated with metastatic progression. RESULTS: Double Prkar1a-Pten thyroid knockout mice develop FTC and recapitulate the histology and metastatic phenotype of the human disease. Analysis of signaling pathways in FTC showed that both human and mouse tumors exhibited strong activation of protein kinase A and mTOR. The development of metastatic disease was associated with the overexpression of genes required for cell movement. CONCLUSIONS: These data imply that the protein kinase A and mTOR signaling cascades are important for the development of follicular thyroid carcinogenesis and may suggest new targets for therapeutic intervention. Mouse models paralleling the development of the stages of human FTC should provide important new tools for understanding the mechanisms of FTC development and progression and for evaluating new therapeutics.
CONTEXT: Thyroid cancer is the most common form of endocrine cancer, and it is a disease whose incidence is rapidly rising. Well-differentiated epithelial thyroid cancer can be divided into papillary thyroid cancer (PTC) and follicular thyroid cancer (FTC). Although FTC is less common, patients with this condition have more frequent metastasis and a poorer prognosis than those with PTC. OBJECTIVE: The objective of this study was to characterize the molecular mechanisms contributing to the development and metastasis of FTC. DESIGN: We developed and characterized mice carrying thyroid-specific double knockout of the Prkar1a and Ptentumor suppressor genes and compared signaling alterations observed in the mouse FTC to the corresponding humantumors. SETTING: The study was conducted at an academic research laboratory. Human samples were obtained from academic hospitals. PATIENTS: Deidentified, formalin-fixed, paraffin-embedded (FFPE) samples were analyzed from 10 control thyroids, 30 PTC cases, five follicular variant PTC cases, and 10 FTC cases. INTERVENTIONS: There were no interventions. MAIN OUTCOME MEASURES: Mouse and patient samples were analyzed for expression of activated cAMP response element binding protein, AKT, ERK, and mammalian target of rapamycin (mTOR). Murine FTCs were analyzed for differential gene expression to identify genes associated with metastatic progression. RESULTS: Double Prkar1a-Pten thyroid knockout mice develop FTC and recapitulate the histology and metastatic phenotype of the human disease. Analysis of signaling pathways in FTC showed that both human and mousetumors exhibited strong activation of protein kinase A and mTOR. The development of metastatic disease was associated with the overexpression of genes required for cell movement. CONCLUSIONS: These data imply that the protein kinase A and mTOR signaling cascades are important for the development of follicular thyroid carcinogenesis and may suggest new targets for therapeutic intervention. Mouse models paralleling the development of the stages of human FTC should provide important new tools for understanding the mechanisms of FTC development and progression and for evaluating new therapeutics.
Authors: Sara Blancquaert; Lifu Wang; Sabine Paternot; Katia Coulonval; Jacques E Dumont; Thurl E Harris; Pierre P Roger Journal: Mol Endocrinol Date: 2010-05-19
Authors: Samantha K McCarty; Motoyasu Saji; Xiaoli Zhang; David Jarjoura; Alfredo Fusco; Vasyl V Vasko; Matthew D Ringel Journal: Endocr Relat Cancer Date: 2010-10-29 Impact factor: 5.678
Authors: David J Mulholland; Linh M Tran; Yunfeng Li; Houjian Cai; Ashkan Morim; Shunyou Wang; Seema Plaisier; Isla P Garraway; Jiaoti Huang; Thomas G Graeber; Hong Wu Journal: Cancer Cell Date: 2011-05-27 Impact factor: 31.743
Authors: Anthony J Trimboli; Carmen Z Cantemir-Stone; Fu Li; Julie A Wallace; Anand Merchant; Nicholas Creasap; John C Thompson; Enrico Caserta; Hui Wang; Jean-Leon Chong; Shan Naidu; Guo Wei; Sudarshana M Sharma; Julie A Stephens; Soledad A Fernandez; Metin N Gurcan; Michael B Weinstein; Sanford H Barsky; Lisa Yee; Thomas J Rosol; Paul C Stromberg; Michael L Robinson; Francois Pepin; Michael Hallett; Morag Park; Michael C Ostrowski; Gustavo Leone Journal: Nature Date: 2009-10-22 Impact factor: 49.962
Authors: Aime T Franco; Roberta Malaguarnera; Samuel Refetoff; Xiao-Hui Liao; Emma Lundsmith; Shioko Kimura; Catrin Pritchard; Richard Marais; Terry F Davies; Lee S Weinstein; Min Chen; Neal Rosen; Ronald Ghossein; Jeffrey A Knauf; James A Fagin Journal: Proc Natl Acad Sci U S A Date: 2011-01-10 Impact factor: 11.205
Authors: Jianling Xie; Godwin A Ponuwei; Claire E Moore; Gary B Willars; Andrew R Tee; Terence P Herbert Journal: Cell Signal Date: 2011-07-06 Impact factor: 4.315
Authors: Michele E Day; Guido M Gaietta; Mira Sastri; Antonius Koller; Mason R Mackey; John D Scott; Guy A Perkins; Mark H Ellisman; Susan S Taylor Journal: J Cell Biol Date: 2011-04-18 Impact factor: 10.539
Authors: Hong Soon Kang; Dhirendra Kumar; Grace Liao; Kristin Lichti-Kaiser; Kevin Gerrish; Xiao-Hui Liao; Samuel Refetoff; Raja Jothi; Anton M Jetten Journal: J Clin Invest Date: 2017-10-30 Impact factor: 14.808
Authors: Amruta Ashtekar; Danielle Huk; Alexa Magner; Krista La Perle; Xiaoli Zhang; José I Piruat; José López-Barneo; Sissy M Jhiang; Lawrence S Kirschner Journal: Endocr Relat Cancer Date: 2017-09-19 Impact factor: 5.678
Authors: Chen Li Chew; Andrea Lunardi; Federico Gulluni; Daniel T Ruan; Ming Chen; Leonardo Salmena; Michiya Nishino; Antonella Papa; Christopher Ng; Jacqueline Fung; John G Clohessy; Junko Sasaki; Takehiko Sasaki; Roderick T Bronson; Emilio Hirsch; Pier Paolo Pandolfi Journal: Cancer Discov Date: 2015-04-16 Impact factor: 39.397
Authors: Devora Champa; Marika A Russo; Xiao-Hui Liao; Samuel Refetoff; Ronald A Ghossein; Antonio Di Cristofano Journal: Endocr Relat Cancer Date: 2014-07-10 Impact factor: 5.678
Authors: Kevin M Riggle; Kimberly J Riehle; Heidi L Kenerson; Rigney Turnham; Miwako K Homma; Machiko Kazami; Bret Samelson; Renay Bauer; G Stanley McKnight; John D Scott; Raymond S Yeung Journal: Pediatr Res Date: 2016-03-08 Impact factor: 3.756
Authors: Amruta Ashtekar; Danielle Huk; Alexa Magner; Krista M D La Perle; Laura Boucai; Lawrence S Kirschner Journal: J Clin Endocrinol Metab Date: 2018-11-01 Impact factor: 5.958